IL34 and colorectal carcinoma: Treatment of DLD1, a CRC cell line, with exogenous IL-34, but not with MCSF-1, activated ERK1/2 MAP kinase pathway thus resulting in enhanced cell proliferation and migration (Figure 2) (39).